LogicBio Therapeutics

OverviewSuggest Edit

LogicBio Therapeutics, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect.

TypePublic
Founded2014
HQLexington, US
Websitelogicbio.com

Latest Updates

Employees (est.) (Dec 2019)41(+79%)
Job Openings6
Share Price (Oct 2020)$6.6 (+11%)
Cybersecurity ratingAMore

Key People/Management at LogicBio Therapeutics

Frederic Chereau

Frederic Chereau

President & CEO, Board Member
Fred Chereau

Fred Chereau

President and Chief Executive Officer, Director
Matthias Jaffé

Matthias Jaffé

Chief Financial Officer
Bryan Yoon

Bryan Yoon

Chief Administrative Officer, General Counsel, Corporate Secretary
Nelson Chau

Nelson Chau

VP, Biology & Translational Research
Kyle Chiang

Kyle Chiang

VP, Product Strategy
Show more

LogicBio Therapeutics Office Locations

LogicBio Therapeutics has an office in Lexington
Lexington, US (HQ)
65 Hayden Ave
Show all (1)

LogicBio Therapeutics Financials and Metrics

LogicBio Therapeutics Revenue

USD

Revenue (Q2, 2020)

965.0k

Net income (Q2, 2020)

(8.2m)

EBIT (Q2, 2020)

(8.0m)

Market capitalization (16-Oct-2020)

209.8m

Closing stock price (16-Oct-2020)

6.6

Cash (30-Jun-2020)

36.7m

EV

189.4m
LogicBio Therapeutics's current market capitalization is $209.8 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

1.4m2.3m6.9m10.4m

R&D expense

2.0m3.6m11.1m30.7m

Operating expense total

3.4m5.9m17.9m41.0m

EBIT

(3.4m)(5.9m)(17.9m)(41.0m)
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.0m965.0k

General and administrative expense

470.0k2.1m2.6m2.5m2.2m3.2m3.0m

R&D expense

580.0k2.4m5.5m7.9m8.9m7.2m5.9m

Operating expense total

1.1m4.6m8.1m10.5m11.0m10.4m8.9m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

1.7m24.6m80.9m33.1m

Prepaid Expenses

86.0k1.1m1.3m2.0m

Current Assets

1.8m25.7m82.2m52.8m

PP&E

215.0k232.0k590.0k1.7m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

12.9m27.9m25.5m38.7m43.2m36.7m

Prepaid Expenses

1.7m1.8m2.0m1.6m3.0m1.9m

Current Assets

14.6m74.3m65.8m64.9m46.3m38.6m

PP&E

487.0k880.0k1.3m1.5m1.6m1.8m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.4m)(5.8m)(17.6m)(40.1m)

Depreciation and Amortization

16.0k43.0k89.0k289.0k

Accounts Payable

340.0k771.0k35.0k(527.0k)

Cash From Operating Activities

(2.4m)(5.8m)(15.3m)(38.7m)
Quarterly
USDQ2, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(1.7m)(5.9m)(10.6m)(7.7m)(17.7m)(28.7m)(9.5m)(17.7m)

Depreciation and Amortization

42.0k39.0k49.0k39.0k104.0k189.0k105.0k226.0k

Accounts Payable

369.0k(273.0k)(570.0k)201.0k448.0k779.0k1.6m(113.0k)

Cash From Operating Activities

(1.3m)(6.3m)(10.6m)(8.2m)(17.0m)(27.0m)(7.5m)(15.8m)
USDFY, 2016

Financial Leverage

1.8 x
Show all financial metrics

LogicBio Therapeutics Operating Metrics

Q2, 2018

Trademarks

2
Show all operating metrics

LogicBio Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

LogicBio Therapeutics Online and Social Media Presence

Embed Graph

LogicBio Therapeutics News and Updates

LogicBio Therapeutics Announces Pricing of Public Offering of Common Stock

LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the pricing of its previously announced underwritten public offering…

LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients

– LogicBio’s First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform –

LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates

FDA Clears IND Application for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients FDA Clears IND Application for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients

LogicBio Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders

LEXINGTON, Mass., June 05, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:  LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that its 2020 Annual Meeting of Stockholders (20…

ALERT, ROSEN, GLOBAL INVESTOR COUNSEL, Reminds LogicBio Therapeutics, Inc. Investors of Important Deadline in Securities Class Action Commenced by the Firm

NEW YORK, March 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. between December 3, 2018 and February 10, 2020, inclusive (the "Class Period") of the important May 18, 2020 lead plaintiff...

LOGICBIO THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against LogicBio Therapeutics, Inc.

NEW YORK, March 27, 2020 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a federal securities class action lawsuit has been filed against of LogicBio Therapeutics, Inc. ("LogicBio" or the Company") (NASDAQ: LOGC) and certain of its officers, on behalf of...
Show more

LogicBio Therapeutics Blogs

LogicBio Reports Full Year 2019 Financial Results and Provides Business Updates

LogicBio Reports Full Year 2019 Financial Results and Provides Business Updates Content Import Mon, 03/16/2020 - 16:06 LogicBio Reports Full Year 2019 Financial Results and Provides Business Updates March 16, 2020 at 4:05 PM EDT This release is a backfill from…

LogicBio Therapeutics Provides Update on FDA Review of Investigational New Drug Application for LB-001 for Methylmalonic Acidemia

LogicBio Therapeutics Provides Update on FDA Review of Investigational New Drug Application for LB-001 for Methylmalonic Acidemia Content Import Mon, 02/10/2020 - 16:06 LogicBio Therapeutics Provides Update on FDA Review of Investigational New Drug Application for LB-001 for Methylmalonic …

LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide™ Candidates

LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide™ Candidates Content Import Tue, 12/17/2019 - 08:01 LogicBio Therapeutics Extends Sponsored Resear…

LogicBio Therapeutics to Present at November Conferences

CAMBRIDGE, Mass. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it will present at the following upcoming healthcare conferences: 10th

LogicBio Therapeutics to Present New Data on Next Generation Capsid Development Program and GeneRide™ Platform Program at the European Society of Gene and Cell Therapy 27th Annual Congress

– Panel Presentation on AAV Manufacturing – CAMBRIDGE, Mass. , Oct. 16, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced upcoming presentations at the

LogicBio Therapeutics to Present at October Conferences

CAMBRIDGE, Mass. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it will present at the following upcoming healthcare conferences:     2019
Show more

LogicBio Therapeutics Frequently Asked Questions

  • When was LogicBio Therapeutics founded?

    LogicBio Therapeutics was founded in 2014.

  • Who are LogicBio Therapeutics key executives?

    LogicBio Therapeutics's key executives are Frederic Chereau, Fred Chereau and Matthias Jaffé.

  • How many employees does LogicBio Therapeutics have?

    LogicBio Therapeutics has 41 employees.

  • Who are LogicBio Therapeutics competitors?

    Competitors of LogicBio Therapeutics include Immunocore, Agenus and Rocket Pharmaceuticals.

  • Where is LogicBio Therapeutics headquarters?

    LogicBio Therapeutics headquarters is located at 65 Hayden Ave, Lexington.

  • Where are LogicBio Therapeutics offices?

    LogicBio Therapeutics has an office in Lexington.

  • How many offices does LogicBio Therapeutics have?

    LogicBio Therapeutics has 1 office.